Biblio

Found 7 results
[ Author(Asc)] Keyword Title Type Year
Filters: Author is Sandro Pignata  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
S. Pignata, Breda, E., Scambia, G., Pisano, C., Zagonel, V., Lorusso, D., Greggi, S., De Vivo, R., Ferrandina, G., Gallo, C., and Perrone, F., A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study, Crit Rev Oncol Hematol, vol. 66, pp. 229-36, 2008.
S. Pignata, De Placido, S., Biamonte, R., Scambia, G., Di Vagno, G., Colucci, G., Febbraro, A., Marinaccio, M., Lombardi, A. V., Manzione, L., Carteni, G., Nardi, M., Danese, S., Valerio, M. R., De Matteis, A., Massidda, B., Gasparini, G., Di Maio, M., Pisano, C., and Perrone, F., Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study, BMC Cancer, vol. 6, p. 5, 2006.
S. Pignata, Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., Lombardi, A. V., Febbraro, A., Scollo, P., Ferro, A., Tamberi, S., Brandes, A., Ravaioli, A., Valerio, M. R., Aitini, E., Natale, D., Scaltriti, L., Greggi, S., Pisano, C., Lorusso, D., Salutari, V., Legge, F., Di Maio, M., Morabito, A., Gallo, C., and Perrone, F., Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial, J Clin Oncol, vol. 29, pp. 3628-35, 2011.
S. Pignata, Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., Cormio, G., Sorio, R., Cavazzini, M. G., Ferrandina, G., Breda, E., Murgia, V., Sacco, C., Cinieri, S., Salutari, V., Ricci, C., Pisano, C., Greggi, S., Lauria, R., Lorusso, D., Marchetti, C., Selvaggi, L., Signoriello, S., Piccirillo, M. C., Di Maio, M., Perrone, F., Cancer, M. Italian Tr, Sein, Gd'Investig, Oncology, M. Negri Gyne, Groups, E. Network of, and Investigators, G. Cancer Int, Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, vol. 15, pp. 396-405, 2014.
S. Pignata, Scambia, G., Savarese, A., Breda, E., Scollo, P., De Vivo, R., Rossi, E., Gebbia, V., Natale, D., Del Gaizo, F., Naglieri, E., Ferro, A., Musso, P., D'Arco, A. M., Sorio, R., Pisano, C., Di Maio, M., Signoriello, G., Annunziata, A., Perrone, F., and Investigators, M. I. T. O., Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial, BMC Cancer, vol. 6, p. 202, 2006.
S. Pignata, Scambia, G., Savarese, A., Breda, E., Sorio, R., Pisano, C., Lorusso, D., Cognetti, F., A. Lombardi, V., Gebbia, V., Scollo, P., Morabito, A., Signoriello, G., and Perrone, F., Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial, Oncology, vol. 76, pp. 49-54, 2009.
S. Pignata and Vermorken, J. B., Ovarian cancer in the elderly., Crit Rev Oncol Hematol, vol. 49, no. 1, pp. 77-86, 2004.